The new drug for type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT-2) inhibitor, is reversible inhibitor of SGLT-2, leading to reduction of renal glucose reabsorption and decrease of plasma glucose, in an insulin-independent manner. In addition to glucose control, the management of coronary risk factors is very important for patients with diabetes. Here we reviewed published articles ab...

Background: Atherosclerosis is a main potential pathology of most cardiovascular diseases. Growing evidence has indicated that dysregulation ferroptosis associated with atherosclerosis. Dapagliflozinas sodiumglucose cotransporter 2 inhibitor (SGLT2i), in view the clinically important benefits sodium-glucose (SGLT2i) dapagliflozin improving outcomes, we aimed to explore its pharmacological effec...

Type 2 diabetes mellitus (T2DM) is a growing worldwide epidemic. Patients face lifelong therapy to control hyperglycemia and prevent the associated complications. There are many medications, with varying mechanisms, available for the treatment of T2DM, but almost all target the declining insulin sensitivity and secretion that are associated with disease progression. Medications with such insuli...

Dapagliflozin is the first novel SGLT2 inhibitor for treatment of Type 2 diabetes. The aim this study was to evaluate its effectiveness and safety in a real-life clinical setting. We analyze data from four hospitals on patients initiated dapagliflozin. HbA1c, weight daily insulin dosage recorded at baseline 6 months follow-up.229 received At baseline, mean HbA1c 82mmol/mol(186) 102 kg(n=159).Th...

Dapagliflozin belongs to a new class of drugs used for the treatment heart failure — sodium-glucose cotransporter type 2 inhibitors (SGLT2i). Based on DAPA-HF study results, dapagliflozin has become first SGLT2i approved symptomatic chronic with reduced ejection fraction. The present review summarizes most important clinical issues related this drug.

A 48-year-old female was admitted to our hospital presenting with a chief complaint of progressive swelling because of diabetic nephrotic syndrome. Dapagliflozin seemed to play a role in accelerating the patient's urinary sodium excretion as well as reducing gross fluid retention despite the fact that her nephrotic condition was resistant to furosemide. Our experience emphasizes a potential nov...

Hyperglycemia is the critical risk factor for diabetic microvascular complications. Several landmark studies, e.g., UK Prospective Diabetes Study (UKPDS) and Diabetes Control and Complications Trial (DCCT), have demonstrated that lowering the HbA1c by 1% decreases microvascular complications by approximately 35% (1,2). Despite the unequivocal evidence for the importance of achieving good glycem...

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo, according to aetiology in patients heart failure (HF) reduced ejection fraction (HFrEF) enrolled Dapagliflozin And Prevention Adverse-outcomes Heart Failure trial (DAPA-HF). Methods results Aetiology was investigator-reported categorized as ischaemic or non-ischaemic. The primary outcome composite an episode worse...